These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 19219408)

  • 1. Pharmacokinetics of digoxin in healthy subjects receiving taranabant, a novel cannabinoid-1 receptor inverse agonist.
    Denker AE; Morelli G; Vessey LK; Li S; Yuan J; Dunbar S; Lewis NM; Taggart W; Wagner JA
    Adv Ther; 2009 Feb; 26(2):230-40. PubMed ID: 19219408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin.
    Schwartz JI; Dunbar S; Yuan J; Li S; Gipson A; Rosko K; Johnson-Levonas AO; Lasseter KC; Addy C; Stoch AS; Wagner JA
    Adv Ther; 2008 Nov; 25(11):1175-90. PubMed ID: 18989636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers.
    Addy C; Rothenberg P; Li S; Majumdar A; Agrawal N; Li H; Zhong L; Yuan J; Maes A; Dunbar S; Cote J; Rosko K; Van Dyck K; De Lepeleire I; de Hoon J; Van Hecken A; Depré M; Knops A; Gottesdiener K; Stoch A; Wagner J
    J Clin Pharmacol; 2008 Jun; 48(6):734-44. PubMed ID: 18508950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers.
    Addy C; Li S; Agrawal N; Stone J; Majumdar A; Zhong L; Li H; Yuan J; Maes A; Rothenberg P; Cote J; Rosko K; Cummings C; Warrington S; Boyce M; Gottesdiener K; Stoch A; Wagner J
    J Clin Pharmacol; 2008 Apr; 48(4):418-27. PubMed ID: 18258750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the steady-state pharmacokinetics of digoxin in healthy adult subjects.
    Liu F; Vessey L; Wenning L; Connolly S; Buckland M; Johnson-Levonas AO; Denker A; Wagner JA; Lai E
    J Clin Pharmacol; 2010 Jul; 50(7):823-8. PubMed ID: 20197486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects.
    Vaz da Silva M; Costa R; Soares E; Maia J; Falcão A; Almeida L; Soares da Silva P
    Fundam Clin Pharmacol; 2009 Aug; 23(4):509-14. PubMed ID: 19500154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of an interaction between tigecycline and digoxin in healthy men.
    Zimmerman JJ; Harper DM; Matschke K; Speth JL; Raible DG; Fruncillo RJ
    Pharmacotherapy; 2007 Jun; 27(6):835-44. PubMed ID: 17542766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, safety, and tolerability of phentermine in healthy participants receiving taranabant, a novel cannabinoid-1 receptor (CB1R) inverse agonist.
    Addy C; Jumes P; Rosko K; Li S; Li H; Maes A; Johnson-Levonas AO; Chodakewitz J; Stoch SA; Wagner JA
    J Clin Pharmacol; 2009 Oct; 49(10):1228-38. PubMed ID: 19783715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokinetics.
    Schwartz JI; Dunbar S; Yuan J; Li S; Miller DL; Rosko K; Johnson-Levonas AO; Lasseter KC; Wagner JA
    J Clin Pharmacol; 2009 Jan; 49(1):72-9. PubMed ID: 18936284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of lasofoxifene on the pharmacokinetics of digoxin in healthy postmenopausal women.
    Roman D; Bramson C; Ouellet D; Randinitis E; Gardner M
    J Clin Pharmacol; 2005 Dec; 45(12):1407-12. PubMed ID: 16291716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of a clinically relevant interaction between etanercept and digoxin.
    Zhou H; Parks V; Patat A; Le Coz F; Simcoe D; Korth-Bradley J
    J Clin Pharmacol; 2004 Nov; 44(11):1244-51. PubMed ID: 15496642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do therapeutic doses of acarbose alter the pharmacokinetics of digoxin?
    Cohen E; Almog S; Staruvin D; Garty M
    Isr Med Assoc J; 2002 Oct; 4(10):772-5. PubMed ID: 12389338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum).
    Johne A; Brockmöller J; Bauer S; Maurer A; Langheinrich M; Roots I
    Clin Pharmacol Ther; 1999 Oct; 66(4):338-45. PubMed ID: 10546917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK; Cheng G; Tang J; Song J; Peng WX
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic interaction of sparfloxacin and digoxin.
    Johnson RD; Dorr MB; Hunt TL; Conway S; Talbot GH
    Clin Ther; 1999 Feb; 21(2):368-79. PubMed ID: 10211539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects.
    Smulders RA; Kuipers ME; Krauwinkel WJ
    Br J Clin Pharmacol; 2006 Aug; 62(2):210-7. PubMed ID: 16842396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
    Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
    Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.
    Kapil R; Nolting A; Roy P; Fiske W; Benedek I; Abramowitz W
    Clin Ther; 2004 Dec; 26(12):2015-25. PubMed ID: 15823765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects.
    Krishna R; Stypinski D; Ali M; Garg A; Gendrano IN; Maes A; DeGroot B; Liu Y; Li S; Connolly SM; Wagner JA; Stoch SA
    Biopharm Drug Dispos; 2011 Dec; 32(9):525-9. PubMed ID: 22031172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.